Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

TWENTE trial - Summary & Results


Published on

A single center prospective single-blinded randimized study to evaluate the Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente

Published in: Health & Medicine, Technology
  • Be the first to comment

  • Be the first to like this

TWENTE trial - Summary & Results

  1. 1. TWENTE (The Real-World EndeavorResolute Versus XIENCE V Drug-ElutingStent Study in Twente)
  2. 2. TWENTE (The Real-World Endeavor Resolute VersusXIENCE V Drug-Eluting Stent Study in Twente)C von Birgelen (Thoraxcentrum Twente, Enschede, the Netherlands)TCT 2011• A single center prospective single-blinded randomized study• Population and treatment: 1391 patients with stable angina or non-ST-elevation ACS Randomized to receive the Xience V stent or the Resolute stent Designed with no limit to the number of lesions or vessels treated and no limit to lesion length or vessel size• Primary outcome: Target vessel failure—a composite of cardiac death, target vessel-related MI, and clinically driven target vessel revascularization (TVR)—at one year
  3. 3. TWENTE: Results• At one year, rates of the primary end point were nearly identical in the two groups• Rates of each component within the composite end point were also very similar• Stent-thrombosis rates, both definite/probable and definite, were very low, and there was no different between groupsOne-year outcomes in Xience V vs Resolute End point Xience V (%) Resolute (%) Log-rank p Primary end point 8.1 8.2 0.94 Cardiac death 1.4 1.0 0.46 Target vessel MI 4.6 4.6 0.98 TVR 2.7 3.3 0.53 Definite/probable stent thrombosis 1.16 0.86 0.59 Definite stent thrombosis 0 0.58 0.12
  4. 4. TWENTE : Commentary*"This confirms the noninferiority of the Resolute stent compared with the Xience Vin a real-word patient population with many acutely diseased and complex patientsand many patients treated for off-label indications . . . You cannot come to any otherconclusion but that the devices are noninferior to each other." - Dr Clemens von Birgelen*All comments from Zotarolimus stent matches everolimus DES in TWENTE(
  5. 5. Become a member of Become a fan on Facebook: Follow us on Twitter: is the leading online source of independent cardiology news.We are the top provider of news and opinions for over 100 000 physicians.